07.05.2024 22:50:20 - dpa-AFX: Myriad Genetics Inc. Q1 Loss Decreases, beats estimates

WASHINGTON (dpa-AFX) - Myriad Genetics Inc. (MYGN) reported Loss for first
quarter that decreased from last year but beat the Street estimates.

The company's bottom line came in at -$26.0 million, or -$0.29 per share. This
compares with -$54.7 million, or -$0.67 per share, in last year's first quarter.

Excluding items, Myriad Genetics Inc. reported adjusted earnings of -$0.5
million or -$0.01 per share for the period.

Analysts on average had expected the company to earn -$0.10 per share, according
to figures compiled by Thomson Reuters. Analysts' estimates typically exclude
special items.

The company's revenue for the quarter rose 11.6% to $202.2 million from $181.2
million last year.

Myriad Genetics Inc. earnings at a glance (GAAP) :

-Earnings (Q1): -$26.0 Mln. vs. -$54.7 Mln. last year.
-EPS (Q1): -$0.29 vs. -$0.67 last year.
-Revenue (Q1): $202.2 Mln vs. $181.2 Mln last year.

-Guidance:
Full year EPS guidance: $0.00 - $0.05
Full year revenue guidance: $820 - $840 Mln


Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
MYRIAD GENETICS DL-,01 897518 Frankfurt 20,600 31.05.24 08:08:00 -0,200 -0,96% 0,000 0,000 20,600 20,600

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH